High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy.
暂无分享,去创建一个
M. Kazatchkine | L. Bélec | L. Weiss | M D Kazatchkine | L Bélec | C Piketty | A Si-Mohamed | C Goujon | M C Hallouin | S Cotigny | L Weiss | C. Piketty | A. Si‐Mohamed | C. Goujon | S. Cotigny | M. Hallouin
[1] N. Young,et al. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. , 1999, Blood.
[2] B Clotet,et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. , 1998, JAMA.
[3] J. Mellors,et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor , 1996, Journal of virology.
[4] M. Kazatchkine,et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease , 1998, AIDS.
[5] J. Condra,et al. Resistance to HIV protease inhibitors , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.
[6] Amalio Telenti,et al. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART) , 1998, The Lancet.
[7] T. Leitner,et al. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[8] N. Shen,et al. Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arrays , 1996, Nature Medicine.
[9] V. Calvez,et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. , 1999, AIDS.